NeuroSense and Lonza Partner to Explore Exosome-based Biomarkers for the Diagnosis and Treatment of Neurodegenerative Disease
Shots:
- Lonza & NeuroSense have entered into a collaboration to research exosome-based biomarkers for the diagnosis and treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS)
- Under the collaboration, NeuroSense will utilize its biomarker utilization experience plus gain access to Lonza's extracellular vesicles expertise on an 'on-demand' basis and Lonza will develop, optimize & qualify a method using NDEs that will be combined to develop NeuroSense's PrimeC
- NeuroSense is evaluating PrimeC in the P-IIb (PARADIGM) study for the treatment of patients with ALS that demonstrated slowing of disease progression. Further biomarker and efficacy data are anticipated in H1’24
Ref: NeuroSense | Image: NeuroSense
Related News:- NeuroSense Collaborated with NeuraLight to Advance ALS Oculometric Biomarkers Using AI and ML
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
